- Home
- HBAN vs WAT Comparison
HBAN vs WAT Comparison
Compare HBAN & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBAN
- WAT
- Stock Information
- Founded
- HBAN 1866
- WAT 1958
- Country
- HBAN United States
- WAT United States
- Employees
- HBAN N/A
- WAT N/A
- Industry
- HBAN Major Banks
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- HBAN Finance
- WAT Industrials
- Exchange
- HBAN Nasdaq
- WAT Nasdaq
- Market Cap
- HBAN 26.0B
- WAT 17.8B
- IPO Year
- HBAN N/A
- WAT 1995
- Fundamental
- Price
- HBAN $17.43
- WAT $303.17
- Analyst Decision
- HBAN Buy
- WAT Hold
- Analyst Count
- HBAN 17
- WAT 14
- Target Price
- HBAN $18.84
- WAT $374.07
- AVG Volume (30 Days)
- HBAN 26.3M
- WAT 577.1K
- Earning Date
- HBAN 10-16-2025
- WAT 10-31-2025
- Dividend Yield
- HBAN 3.56%
- WAT N/A
- EPS Growth
- HBAN 26.38
- WAT 10.77
- EPS
- HBAN 1.34
- WAT 11.09
- Revenue
- HBAN $7,242,000,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- HBAN $18.09
- WAT $7.19
- Revenue Next Year
- HBAN $8.40
- WAT $6.40
- P/E Ratio
- HBAN $13.01
- WAT $27.33
- Revenue Growth
- HBAN 7.91
- WAT 5.89
- 52 Week Low
- HBAN $11.92
- WAT $275.05
- 52 Week High
- HBAN $18.45
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- HBAN 52.42
- WAT 52.92
- Support Level
- HBAN $17.54
- WAT $294.96
- Resistance Level
- HBAN $17.86
- WAT $303.24
- Average True Range (ATR)
- HBAN 0.32
- WAT 8.97
- MACD
- HBAN -0.04
- WAT 0.70
- Stochastic Oscillator
- HBAN 27.71
- WAT 69.04
About HBAN Huntington Bancshares Incorporated
Huntington is a regional US bank with around $208 billion in assets and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.